End-of-day quote
Other stock markets
|
||
- CHF | - |
Apr. 26 | Roche: positive CHMP opinion for Alecensa | CF |
Apr. 26 | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
Sales 2024 * | 60.04B 65.65B | Sales 2025 * | 63.83B 69.8B | Capitalization | 178B 195B |
---|---|---|---|---|---|
Net income 2024 * | 13.31B 14.56B | Net income 2025 * | 14.75B 16.13B | EV / Sales 2024 * | 3.21 x |
Net Debt 2024 * | 14.24B 15.57B | Net Debt 2025 * | 8.17B 8.93B | EV / Sales 2025 * | 2.92 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
11.8
x | Employees | - |
Yield 2024 * |
4.4% | Yield 2025 * |
4.55% | Free-Float | 88.91% |
Latest transcript on Roche Holding Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 65 | 95-12-31 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-6.26% | 145B | |
-11.77% | 144B |